Oncothyreon (ONTY) Misses Q2 EPS by 3c

Oncothyreon (NASDAQ: ONTY) reported Q2 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08).

As of June 30, 2015, Oncothyreon's cash, cash equivalents and investments were $70.0 million, compared to $63.7 million at December 31, 2014, an increase of $6.3 million, or 9.9 percent.

Oncothyreon currently expects operating expenses in 2015 to be lower than in 2014, which included the upfront payment to Array BioPharma Inc. for the exclusive license to ONT-380. Oncothyreon currently expects cash used in operations in 2015 to be approximately $32.0 - $34.0 million.

For earnings history and earnings-related data on Oncothyreon (ONTY) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• J.B. Hunt Transport Services (JBHT) PT Raised to $261 at Stifel Into Q2 Earnings
• Sanuwave Q2 2026 revenue tops revised guidance range